stockrowDianthus Therapeutics, Inc.
DNTH Healthcare Biotechnology
Dianthus Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, down 67.3% from fiscal 2024.
- Revenue
- +205.6%
- EPS
- +16.1%
- Free cash flow
- −65.9%
Quarter to September 2026, against a year earlier
Follow DNTH
Alert me
Dianthus Therapeutics, Inc. (DNTH) Shares outstanding
Dianthus Therapeutics, Inc.'s shares outstanding at the end of fiscal 2025 was $38.6M, up 15.9% from $33.3M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $57.3M. Over the past ten years it has ranged from $9.3K (fiscal 2016) to $38.6M (fiscal 2025) — the current reading is the highest in ten years. Dianthus Therapeutics, Inc. ranks 270th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $38.6M | 15.92% |
| FY2024 | $33.3M | 546.50% |
| FY2023 | $5.2M | 489.59% |
| FY2022 | $874.0K | (74.55%) |
| FY2021 | $3.4M | 25.11% |
| FY2020 | $2.7M | 18.66% |
| FY2019 | $2.3M | 101.29% |
| FY2018 | $1.1M | 889.92% |
| FY2017 | $116.1K | 1,148.39% |
| FY2016 | $9.3K | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $57.3M | 2.34% |
| Jun 2026 | $56.0M | 16.65% |
| Mar 2026 | $48.0M | 24.38% |
| Dec 2025 | $38.6M | 2.18% |
| 33 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| ERAS Erasca, Inc. compare | $311.3M |
| LEGN Legend Biotech Corporation Sponsored ADR compare | $193.8M |
| COGT Cogent Biosciences, Inc. compare | $171.0M |
| EWTX Edgewise Therapeutics, Inc. compare | $120.9M |
| DFTX Definium Therapeutics, Inc. compare | $110.7M |
| CRSP CRISPR Therapeutics AG compare | $96.7M |
| TVTX Travere Therapeutics, Inc. compare | $94.6M |
| DNTH Dianthus Therapeutics, Inc. | $57.3M |
| MANE Veradermics Incorporated compare | $40.4M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on DNTH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Book value per share
- Revenue growth
- Altman Z-score
- Beneish M-score
- The full statement